{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:06:41Z","timestamp":1793203601052,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12-AR084222"],"award-info":[{"award-number":["K12-AR084222"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.mayocp.2024.07.006","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T23:51:36Z","timestamp":1732665096000},"page":"265-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3349-3676","authenticated-orcid":false,"given":"Rene","family":"Rivera Gutierrez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Tama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"Bechenati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Casta\u00f1eda Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela K.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson W.","family":"McNally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Fansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Anazco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-7334","authenticated-orcid":false,"given":"Maria D.","family":"Hurtado Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2024.07.006_bib1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3-4","key":"10.1016\/j.mayocp.2024.07.006_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00508-018-1434-9","article-title":"Overweight and obesity in type 1 diabetes equal those of the general population","volume":"131","author":"Fellinger","year":"2019","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"10.1016\/j.mayocp.2024.07.006_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/M22-3078","article-title":"Prevalence and management of obesity in U.S. adults with type 1 diabetes","volume":"176","author":"Fang","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.mayocp.2024.07.006_bib4","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.2147\/DMSO.S223618","article-title":"Obesity in patients with type 1 diabetes: links, risks and management challenges","volume":"14","author":"Vilarrasa","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.mayocp.2024.07.006_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"23","key":"10.1016\/j.mayocp.2024.07.006_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314631","article-title":"Tirzepatide: A Systematic Update","volume":"23","author":"Forzano","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1692","key":"10.1016\/j.mayocp.2024.07.006_bib7","doi-asserted-by":"crossref","first-page":"205","DOI":"10.58347\/tml.2023.1692c","article-title":"Tirzepatide (Zepbound) for chronic weight management","volume":"65","year":"2023","journal-title":"Med Lett Drugs Ther"},{"issue":"8","key":"10.1016\/j.mayocp.2024.07.006_bib8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2174\/1871530322666221004151212","article-title":"Tirzepatide: a new generation therapeutic for diabetes type 2","volume":"23","author":"Al-Horani","year":"2023","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.mayocp.2024.07.006_bib9","doi-asserted-by":"crossref","DOI":"10.1177\/19322968231223991","article-title":"Efficacy and safety of tirzepatide in adults with type 1 diabetes: a proof of concept observational study","author":"Akturk","year":"2024","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"6","key":"10.1016\/j.mayocp.2024.07.006_bib10","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1089\/dia.2024.0050","article-title":"Efficacy and safety of tirzepatide in overweight and obese adult patients with type 1 diabetes","volume":"26","author":"Garg","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"10.1016\/j.mayocp.2024.07.006_bib11","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s13300-024-01592-9","article-title":"Changes in basal and bolus insulin requirements with tirzepatide as an adjunctive therapy in adults with type 1 diabetes using tandem control-IQ","volume":"15","author":"Karakus","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.mayocp.2024.07.006_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/19322968241245680","article-title":"Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity","author":"Klein","year":"2024","journal-title":"J\u00a0Diabetes Sci Technol"},{"issue":"10402","key":"10.1016\/j.mayocp.2024.07.006_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"10300","key":"10.1016\/j.mayocp.2024.07.006_bib14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.mayocp.2024.07.006_bib15","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"issue":"10295","key":"10.1016\/j.mayocp.2024.07.006_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2024.07.006_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10313","key":"10.1016\/j.mayocp.2024.07.006_bib18","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2024.07.006_bib19","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.mayocp.2024.07.006_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.mayocp.2024.07.006_bib21","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dom.14090","article-title":"Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss","volume":"22","author":"Ghanim","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.mayocp.2024.07.006_bib22","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial \u2014 a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.mayocp.2024.07.006_bib23","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/clinem\/dgac618","article-title":"Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: a real-world study","volume":"108","author":"Edwards","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mayocp.2024.07.006_bib24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/clinem\/dgad471","article-title":"Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: an updated systematic review and meta-analysis","volume":"109","author":"Park","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"19","key":"10.1016\/j.mayocp.2024.07.006_bib25","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2024.07.006_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2024.07.006_bib27","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.13125","article-title":"Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials","volume":"20","author":"Davies","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"10.1016\/j.mayocp.2024.07.006_bib28","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2024.07.006_bib29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2024.07.006_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.aace.2023.04.010","article-title":"Diabetic ketoacidosis in a patient with type i diabetes treated with a closed-loop sensor-augmented insulin infusion system","volume":"9","author":"Sharma","year":"2023","journal-title":"AACE Clin Case Rep"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624003501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619624003501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T08:16:03Z","timestamp":1738570563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619624003501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0025619624003501"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.07.006","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Tirzepatide on Body Weight and Diabetes Control in Adults With Type 1 Diabetes and Overweight or Obesity","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2024.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}